M Craig Hall

Summary

Publications

  1. ncbi request reprint Bladder cancer
    Suzanne E Patton
    Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Curr Opin Oncol 14:265-72. 2002
  2. ncbi request reprint Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update
    M Craig Hall
    American Urological Association Education and Research, Inc, USA
    J Urol 178:2314-30. 2007
  3. ncbi request reprint Bladder cancer
    Lester S Borden
    Department of Urology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Curr Opin Oncol 15:227-33. 2003
  4. ncbi request reprint Recent advances in the treatment of bladder cancer
    Eric S Gwynn
    Department of Urology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Expert Rev Anticancer Ther 5:1023-30. 2005
  5. ncbi request reprint Bladder cancer
    Lester S Borden
    Department of Urology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Curr Opin Oncol 17:275-80. 2005
  6. ncbi request reprint Contemporary management of the urethra in patients after radical cystectomy for bladder cancer
    Peter E Clark
    Department of Urology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27104, USA
    Urol Clin North Am 32:199-206. 2005
  7. ncbi request reprint Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
    Joseph J Phillips
    Department of Urology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Urol Oncol 25:196-200. 2007

Detail Information

Publications7

  1. ncbi request reprint Bladder cancer
    Suzanne E Patton
    Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Curr Opin Oncol 14:265-72. 2002
    ..Other active agents in bladder cancer include ifosfamide, carboplatin, docetaxel, and vinorelbine, and various doublets of these agents are being tested in phase II trials, with promising results...
  2. ncbi request reprint Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update
    M Craig Hall
    American Urological Association Education and Research, Inc, USA
    J Urol 178:2314-30. 2007
  3. ncbi request reprint Bladder cancer
    Lester S Borden
    Department of Urology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Curr Opin Oncol 15:227-33. 2003
    ....
  4. ncbi request reprint Recent advances in the treatment of bladder cancer
    Eric S Gwynn
    Department of Urology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Expert Rev Anticancer Ther 5:1023-30. 2005
    ..The current methods of detection, as well as available therapeutic treatment options are reviewed...
  5. ncbi request reprint Bladder cancer
    Lester S Borden
    Department of Urology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Curr Opin Oncol 17:275-80. 2005
    ..A brief overview of all aspects of bladder cancer including the etiology, diagnosis, and treatment are discussed with a focus on recent advances...
  6. ncbi request reprint Contemporary management of the urethra in patients after radical cystectomy for bladder cancer
    Peter E Clark
    Department of Urology, Wake Forest University Health Sciences, Medical Center Boulevard, Winston Salem, NC 27104, USA
    Urol Clin North Am 32:199-206. 2005
    ....
  7. ncbi request reprint Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer?
    Joseph J Phillips
    Department of Urology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Urol Oncol 25:196-200. 2007
    ..To assess whether a delay in initiating definitive therapy for clinically localized prostate cancer affects outcome...